Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose ambroxol for amyotrophic lateral sclerosis
ACTRN12622001380785Phase 2Completed
- Sponsor
- Florey Institute of Neuroscience and Mental Health
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Ambroxol with Placebo (2 arms). Primary endpoint: Time to composite clinical event. Started Jun 2023; status: completed.
02
Drugs
ambroxol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ACTRN12622001380785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001380785.